Intelligence · Patent portfolio
Theravance Biopharma Ireland Patents
Full USPTO pharma patent portfolio for Theravance Biopharma Ireland — grant dates, expiration, and drug cross-links.
- Patents
- 635
- Expiring ≤24m
- 58
Quick answer
Theravance Biopharma Ireland has 635 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 58 expire within 24 months — use filters for patent-cliff planning.
-
US 6635764
Therapeutic ureas
expired -
US 6620781
Glycopeptide carboxy-saccharide derivatives
expired -
US 6576791
Local anesthetic compounds and uses
expired -
US 6576793
&bgr;2-adrenergic receptor agonists
expired -
US 6566509
Multivalent macrolide antibiotics
expired -
US 6541669
&bgr;2-adrenergic receptor agonists
expired -
US 6518242
Derivatives of glycopeptide antibacterial agents
expired -
US 6495681
Local anesthetic compounds and uses
expired -
US 6479498
Sodium channel drugs and uses
expired -
US 6455669
Glycopeptide derivatives and pharmaceutical compositions containing the same
expired -
US 6436919
Local anesthetic compounds
expired
Frequently asked questions
How many patents does Theravance Biopharma Ireland have?
635 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Theravance Biopharma Ireland patents expire?
58 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory